2024
Multi-day vs single-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis
Chow R, Celio L, Im J, Caini S, Eng L, Prsic E, Scotté F, Aapro M. Multi-day vs single-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. Supportive Care In Cancer 2024, 32: 736. PMID: 39432169, DOI: 10.1007/s00520-024-08934-0.Peer-Reviewed Original ResearchMeSH KeywordsAntiemeticsAntineoplastic AgentsDexamethasoneDrug Administration ScheduleHumansNauseaNeoplasmsRandomized Controlled Trials as TopicVomitingConceptsDexamethasone-sparing regimenChemotherapy-induced nausea and vomitingModerately emetogenic chemotherapyHighly emetogenic chemotherapyRandomized controlled trialsComplete responseMeta-analysisEmetogenic chemotherapyNo vomitingRescue medicationProphylaxis of chemotherapy-induced nausea and vomitingSystematic reviewSchedule of dexamethasoneNausea and vomitingChemotherapy-induced nauseaResultsTen trialsAntiemetic regimenCumulative meta-analysisEffect estimatesSafety profileComprehensive systematic reviewMethodsOvid MEDLINERegimensAdult cancer patientsCancer patients
2023
Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)—a systematic review and individual patient data meta-analysis
Chow R, Yin L, Baqri W, Huang R, Boldt G, Younus J, Lock M, Prsic E, Zimmermann C, Herrstedt J. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)—a systematic review and individual patient data meta-analysis. Supportive Care In Cancer 2023, 31: 505. PMID: 37535218, DOI: 10.1007/s00520-023-07978-y.Peer-Reviewed Original ResearchMeSH KeywordsAntiemeticsAntineoplastic AgentsHumansNauseaNeoplasmsPrevalenceProspective StudiesVomitingConceptsChemotherapy-induced nauseaIndividual patient dataDay 4Individual patient-level dataPatient dataPatient-level dataStepwise logistic regressionEmetogenic chemotherapyChemotherapy regimenChemotherapy regimensPatient demographicsCochrane CENTRALResultsA totalOverall prevalenceCINVNauseaVomitingPatientsEligible articlesSystematic reviewAntineoplastic agentsStudy authorsLogistic regressionMethodsThis reviewSignificant risk
2022
Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis
Chow R, Novosel M, So OW, Bellampalli S, Xiang J, Boldt G, Winquist E, Lock M, Lustberg M, Prsic E. Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis. BMJ Supportive & Palliative Care 2022, 13: 27-34. PMID: 36194493, DOI: 10.1136/spcare-2022-003815.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsDuloxetine HydrochlorideHumansPeripheral Nervous System DiseasesRandomized Controlled Trials as TopicConceptsChemotherapy-induced peripheral neuropathyTreatment of CIPNDuloxetine usePeripheral neuropathyRisk ratioPrevention of CIPNSystematic reviewUse of duloxetineSummary risk ratiosClinical practice recommendationsHigh-quality trialsDerSimonian-Laird modelComprehensive systematic reviewCochrane CENTRALSafety profileDatabase inceptionHuman trialsDuloxetinePractice recommendationsLimited evidencePreventionTrialsNeuropathyTreatmentReview
2021
Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis
Chow R, Navari RM, Terry B, DeAngelis C, Prsic EH. Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis. Supportive Care In Cancer 2021, 30: 1015-1018. PMID: 34613472, DOI: 10.1007/s00520-021-06606-x.Peer-Reviewed Original ResearchMeSH KeywordsAntiemeticsAntineoplastic AgentsBenzodiazepinesHumansNauseaNetwork Meta-AnalysisOlanzapineVomiting